Age-specific prevalence for mf or LF antigen in Dokan Tofa and Piapung sentinel villages.

<p>Panel A: Dokan Tofa pretreatment prevalence by age group (n = 418). Panel B: Piapung pretreatment prevalence by age group (n = 400). Panel C: Dokan Tofa prevalence by age group after 6 rounds of MDA (n = 223). Panel D: Piapung prevalence by age group after 6 rounds of MDA (n = 280). Boxes show numbers sampled in each age group. Pretreatment sample for mf is different from <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t002" target="_blank">Table 2</a> because ages were not available on all persons tested. Pretreatment sample for antigen for these SVs are different than baseline figure shown in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t003" target="_blank">Table 3</a> because 1999/2000 mapping data were added to baseline calculation in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#pntd-0001346-t003" target="_blank">Table 3</a> (see <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001346#s2" target="_blank">Methods</a>).</p>